UK's Proteome Sciences H1 revenue flat, loss narrows on lower costs
UK's Proteome Sciences H1 revenue flat, loss narrows on lower costs
Overview
UK contract proteomics provider's H1 2026 revenue was flat yr/yr at £1.87 mln
Proteomics services revenue fell due to timing, while TMT sales and royalties increased
Gross profit rose and net loss narrowed as costs declined
Outlook
Proteome Sciences expects full-year 2026 services revenue to significantly increase over 2025
Company anticipates continued recovery in TMT® revenues in the second half of 2026
Company sees prospects for future revenue growth from new tags and evolving proteomics workflows
Result Drivers
SERVICES REVENUE TIMING - Co said lower H1 proteomics services revenue was due to timing issues, with expectations for higher volumes in H2
TMT SALES RECOVERY - Co said TMT reagent sales and royalties rose 24% in H1, reflecting recovery in US grant funding and market demand
COST REDUCTION - Co attributed lower operating loss to an 11% reduction in cost of sales and administrative expenses
Company press release: ID:nRSP9038Ua
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
H1 Gross Profit |
| GBP 436,000 |
|
Reuters Recommended Reads
Sept 15 - UK's Trustpilot shares slump as unchanged outlook disappoints investors
Sept 15 - UK's Wickes Group H1 revenue rises 2.1%, profit up 1.1%
Sept 15 - UK's McBride full-year revenue rises 0.8%, as profit falls
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)